Alzheimer’s disease mutations in APP but not γ-secretase modulators affect epsilon-cleavage-dependent AICD production

Clinical trials of γ-secretase inhibitors to treat Alzheimer’s disease show that side effects occur from their non-selective action. Dimitrov et al. show that improved second generation γ-secretase modulators spare cleavage sites of substrate proteins that are implicated in the side effects.